Nat CancerJClubNext-generation cancer therapeutics.Nature Cancer · 1 Sept 2026 · EditorialNext-generation cancer therapeutics.Abstract ↗AI briefThe abstract is read at the publisher; the brief is JClub's.The AI brief for this paper is being written. Open it in JClub to read the paper with the brief as soon as it lands.Read the brief in JClub →Related in JClubCancer DiscovJClubIn Regulatory First, Myeloma Drug Approved Based on MRD Negativity.Cancer Discovery · 21 Aug 2026 · NewsFDA approves iberdomide for multiple myeloma based on minimal residual disease negativity, marking the first such approval for the disease.In the newsOpenShareCopy linkPost on XPost on BlueskyShare on LinkedInhttps://jclub.com.au/a/42627098Open in JClub
Cancer DiscovJClubIn Regulatory First, Myeloma Drug Approved Based on MRD Negativity.Cancer Discovery · 21 Aug 2026 · NewsFDA approves iberdomide for multiple myeloma based on minimal residual disease negativity, marking the first such approval for the disease.In the newsOpenShareCopy linkPost on XPost on BlueskyShare on LinkedInhttps://jclub.com.au/a/42627098Open in JClub